SYNOCURE® 9422 BA 70 MY (E20822)

Non-Isocyanate Cured Acrylic

ARKEMA COATING RESINS

Product

SYNOCURE® 9422 BA 70 MY is an acid functional acrylic resin designed to crosslink at room temperature with epoxy resins to give high solids content isocyanate-free two-pack coating systems.

Coatings based on this resin are especially suitable for protection and maintenance in areas where **Application details** rapid drying, hardness and abrasion resistance are required.

> SYNOCURE® 9422 BA 70 MY has been designed to react with economic bisphenol A type epoxies and still maintain good exterior durability.

Performance Benefits

- Coatings formulation with VOC at or below 420g/l at application viscosity
- Fast drying
- Good exterior durability

Polymer Type

Solventborne Acrylic

Sales
Specifications

(provisional*)

Solid Content at 125°C, % (ISO 3251)

68 - 72 3000 - 6000

Viscosity at 25°C, mPa.s (ISO 3219) Colour, Gardner scale (ISO 4630)

5 max 44 - 52

Acid value, mg KOH/g (ISO 2114) * These specifications are subject to change in the light of manufacturing experience, up to the point of full commercialisation

Other Characteristics¹ Density / Specific Gravity at 25°C, g/ml (ISO 2811)

Butyl acetate 1.00

Note: Acid value and/or Hydroxyl value quoted relative to solid resin

1 The data provided for these properties are typical values, intended only as guides, and should not be construed as sales specifications

RECOMMENDATIONS FOR USE

SYNOCURE® 9422 BA 70 MY is designed for use with low viscosity epoxy resins of epoxy equivalent weight 180-190 (1)

Active hydrogen equivalent weight of SYNOCURE® 9422 BA 70 MY is 1145 based on solid resin. A stochiometric mixing ratio of 1/1 to 1.25 / 1 epoxy / active hydrogen equivalents is recommended although minor deviations from this will have little effect on performance.

This isocyanate-free system is suitable for use with a wide range of both organic and inorganic pigments. As with other reactive two-component systems it is strongly recommended that all pigments are checked for stability with the system before commercialisation.

Formulation Guidelines

SOLUBILITY

Volatile

Aromatic hydrocarbons such as xylene together with minor proportions of esters and alcohols are the most suitable.

OTHER ADDITIVES

Hindered amine light stabilisers (HALS) (2) are strongly recommended as additives for these acrylic/epoxy systems.

SYNOCURE® 9422 BA 70 MY should only be used in applications consistent with the above recommendations. Proposals to use the resin in alternative systems should be discussed with Arkema before any action is taken.

Notes: (1) Araldite® GY250 (Hunstman) or Epikote™ Resin 828 (Momentive), (2) Tinuvin® 292 (Ciba) at 2% (based on total resin solids)



Product Safety	Please refer to the corresponding Safety Data Sheet.
Storage & Handling	SYNOCURE® 9422 BA 70 MY should be stored indoors in the original, unopened and undamaged container, in a dry place at a temperature not exceeding 30°C. Exposure to direct sunlight should be avoided. In the above mentioned storage conditions the shelf life of the resin will be 12 months

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, Arkema expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in medical devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html) Arkema has designated medical grades to be used for such medical device applications. Products that have not been designated as medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids. In Arkema strictly prohibits the use of any Arkema products in medical device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

Arkema Coating Resins Malaysia Sdn Bhd



